Cyclopharm Past Earnings Performance
Past criteria checks 0/6
Cyclopharm's earnings have been declining at an average annual rate of -14.8%, while the Medical Equipment industry saw earnings growing at 8.3% annually. Revenues have been growing at an average rate of 12.4% per year.
Key information
-14.8%
Earnings growth rate
-7.9%
EPS growth rate
| Medical Equipment Industry Growth | 5.8% |
| Revenue growth rate | 12.4% |
| Return on equity | -19.6% |
| Net Margin | -38.7% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
What You Can Learn From Cyclopharm Limited's (ASX:CYC) P/SAfter Its 26% Share Price Crash
Oct 28
Is Cyclopharm Limited (ASX:CYC) Trading At A 25% Discount?
Apr 18Companies Like Cyclopharm (ASX:CYC) Are In A Position To Invest In Growth
Mar 31Companies Like Cyclopharm (ASX:CYC) Can Afford To Invest In Growth
Oct 17Companies Like Cyclopharm (ASX:CYC) Can Afford To Invest In Growth
Jun 09Analyst Forecasts For Cyclopharm Limited (ASX:CYC) Are Surging Higher
Mar 06Here's Why We're Not At All Concerned With Cyclopharm's (ASX:CYC) Cash Burn Situation
Mar 02We Think Cyclopharm (ASX:CYC) Can Afford To Drive Business Growth
Oct 22Cyclopharm Limited's (ASX:CYC) Analyst Just Slashed This Year's Estimates
Jun 29Shareholders Will Probably Hold Off On Increasing Cyclopharm Limited's (ASX:CYC) CEO Compensation For The Time Being
Apr 27Rainbows and Unicorns: The Cyclopharm Limited (ASX:CYC) Analyst Just Became A Lot More Optimistic
Mar 01Cyclopharm (ASX:CYC) Has Rewarded Shareholders With An Exceptional 401% Total Return On Their Investment
Feb 07Is Cyclopharm Limited (ASX:CYC) Popular Amongst Insiders?
Jan 02We're Not Very Worried About Cyclopharm's (ASX:CYC) Cash Burn Rate
Dec 06Revenue & Expenses Breakdown
How Cyclopharm makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 24 | -9 | 26 | 1 |
| 31 Mar 24 | 26 | -7 | 23 | 2 |
| 31 Dec 23 | 27 | -5 | 21 | 4 |
| 30 Sep 23 | 29 | -6 | 20 | 5 |
| 30 Jun 23 | 30 | -7 | 19 | 6 |
| 31 Mar 23 | 27 | -7 | 19 | 5 |
| 31 Dec 22 | 25 | -7 | 19 | 3 |
| 30 Sep 22 | 24 | -5 | 18 | 2 |
| 30 Jun 22 | 23 | -4 | 18 | 1 |
| 31 Mar 22 | 21 | -4 | 17 | 1 |
| 31 Dec 21 | 20 | -5 | 17 | 2 |
| 30 Sep 21 | 20 | -5 | 16 | 2 |
| 30 Jun 21 | 20 | -4 | 16 | 3 |
| 31 Mar 21 | 19 | -5 | 15 | 3 |
| 31 Dec 20 | 18 | -6 | 14 | 4 |
| 30 Sep 20 | 17 | -6 | 14 | 4 |
| 30 Jun 20 | 16 | -6 | 13 | 4 |
| 31 Mar 20 | 17 | -4 | 13 | 4 |
| 31 Dec 19 | 17 | -3 | 12 | 4 |
| 30 Sep 19 | 16 | -3 | 11 | 4 |
| 30 Jun 19 | 16 | -2 | 10 | 4 |
| 31 Mar 19 | 16 | -1 | 10 | 4 |
| 31 Dec 18 | 16 | 0 | 9 | 3 |
| 30 Sep 18 | 16 | 0 | 9 | 3 |
| 30 Jun 18 | 16 | -1 | 9 | 3 |
| 31 Mar 18 | 16 | -1 | 9 | 3 |
| 31 Dec 17 | 16 | -2 | 9 | 3 |
| 30 Sep 17 | 15 | -1 | 8 | 3 |
| 30 Jun 17 | 14 | -1 | 8 | 2 |
| 31 Mar 17 | 15 | 0 | 8 | 2 |
| 31 Dec 16 | 15 | 1 | 8 | 1 |
| 30 Sep 16 | 14 | 3 | 7 | 1 |
| 30 Jun 16 | 14 | 5 | 7 | 1 |
| 31 Mar 16 | 13 | 5 | 7 | 1 |
| 31 Dec 15 | 13 | 5 | 6 | 1 |
| 30 Sep 15 | 12 | 4 | 6 | 1 |
| 30 Jun 15 | 11 | 3 | 6 | 1 |
| 31 Mar 15 | 11 | 4 | 7 | 1 |
| 31 Dec 14 | 12 | 4 | 7 | 0 |
| 30 Sep 14 | 13 | -2 | 7 | 0 |
| 30 Jun 14 | 14 | -8 | 8 | 0 |
| 31 Mar 14 | 13 | -9 | 8 | 0 |
| 31 Dec 13 | 12 | -10 | 8 | 0 |
Quality Earnings: CYC is currently unprofitable.
Growing Profit Margin: CYC is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CYC is unprofitable, and losses have increased over the past 5 years at a rate of 14.8% per year.
Accelerating Growth: Unable to compare CYC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CYC is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (18.7%).
Return on Equity
High ROE: CYC has a negative Return on Equity (-19.59%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 06:35 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Cyclopharm Limited is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Russell Wright | Barclay Pearce Capital Pty Limited |
| John Hester | Bell Potter |
| Sarah Mann | MA Moelis Australia Securities Pty Ltd |